Wall Street Zen Downgrades Phreesia (NYSE:PHR) to Hold

Phreesia (NYSE:PHR) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other research firms also recently commented on PHR. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Phreesia in a research note on Monday, August 31st. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 price objective on shares of Phreesia in a research note on Thursday. Piper Sandler lowered shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price for the company. in a report on Thursday, May 28th. Citigroup restated a “market perform” rating on shares of Phreesia in a research note on Friday. Finally, DA Davidson decreased their target price on shares of Phreesia from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Phreesia currently has a consensus rating of “Hold” and a consensus price target of $15.25.

Phreesia Trading Up 0.3%

NYSE:PHR opened at $10.97 on Friday. Phreesia has a one year low of $7.77 and a one year high of $30.43. The business has a fifty day moving average price of $11.25 and a 200-day moving average price of $10.46. The firm has a market capitalization of $680.91 million, a price-to-earnings ratio of 64.53 and a beta of 0.86. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.76 and a quick ratio of 1.76.

Phreesia (NYSE:PHR) last released its earnings results on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.06). Phreesia had a net margin of 2.06% and a return on equity of 5.22%. The company had revenue of $129.46 million for the quarter, compared to analysts’ expectations of $129.06 million. During the same quarter last year, the firm posted $0.01 earnings per share. Phreesia’s revenue for the quarter was up 10.4% on a year-over-year basis. Sell-side analysts forecast that Phreesia will post 0.38 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Van ECK Associates Corp lifted its position in shares of Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after buying an additional 1,102 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in Phreesia by 354.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after buying an additional 2,149 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Phreesia by 1,119.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock valued at $27,000 after buying an additional 3,001 shares in the last quarter. New York State Teachers Retirement System purchased a new position in Phreesia during the 1st quarter valued at approximately $44,000. Finally, Tower Research Capital LLC TRC increased its stake in Phreesia by 332.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock worth $160,000 after acquiring an additional 4,313 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.